
	Where results make sense

Topic: Serono

Related Topics

Lists of companies

Denner

List of Hungarian companies

Migros

ASCOM

Firmenich

Metro Group

Rieter

AMAG

KamKorp

Ciba Specialty Chemicals

List of pharmaceutical companies

UBS AG

Zurich Financial Services

Omega Watches

	Serono
		Serono ist weltweit führend bei der Behandlung von Fruchtbarkeitsstörungen; das Unternehmen konzentriert sich auf Marktnischen.
		Als weltweit führendes Unternehmen in der Behandlung von Fruchtbarkeitsstörungen nimmt Serono auch in den Bereichen Neurologie sowie Stoffwechsel- und Wachstumsstörungen eine bedeutende Stellung ein.
		Serono ist in über 45 Ländern tätig, seine Produkte werden in über 100 Ländern verkauft.
	www.oracle.com /global/de/pub/artikel/2001/serono.html (1206 words)

	Boston.com / Business / Size of charge drives down Serono stock
		Several analysts said they were surprised by the size of the charge that Serono SA of Geneva took in the first quarter and disclosed in an earnings report issued late Thursday after markets had closed.
		Serono said it expects the charge would cover the cost of settling an investigation into the marketing of its drug Serostim, a growth hormone to treat AIDS wasting.
		In its earnings release, Serono said that talks with prosecutors in the office of Michael J. Sullivan, US attorney for Massachusetts, have advanced to the point where the settlement charge was appropriate.
	www.boston.com /business/articles/2005/04/23/size_of_charge_drives_down_serono_stock (573 words)

	Ex-Serono executive charged in bribery case - The Boston Globe
		Federal prosecutors yesterday alleged that a former sales director for Serono Inc. offered doctors bribes in return for prescribing its AIDS treatment as part of a marketing program at the Swiss drug company, whose main US offices are in Rockland.
		Serono disclosed in 2002 that it received a subpoena concerning Serostim, but would not describe the inquiry.
		According to Slavitt, Stupak has also filed a civil lawsuit against Serono, still under seal in US District Court, alleging the company did not live up to its obligations to pay his legal expenses for the federal investigation under the terms of a severance agreement when Stupak left the company in late 2000.
	www.boston.com /business/articles/2004/12/16/ex_serono_executive_charged_in_bribery_case (672 words)

	Serono France - Accueil
		Serono a la vocation de développer des produits de biotechnologie innovants et d'utilisation simple, destinés à aider les couples ayant des troubles de la fertilité.
		Serono a été l’un des premiers laboratoires à avoir proposé l’hormone de croissance pour traiter les troubles de la croissance chez l’enfant.
		Serono continue à tout mettre en œuvre pour aider les patients enfants et adultes à suivre leur traitement par la mise à disposition d’auto-injecteur.
	www.serono.fr (151 words)

	Serono, Inc. and Pfizer Inc. \| Privacy Policy
		Serono may use this information to analyze and enhance the Web Site, and may aggregate this information and share such aggregated information with business partners, sponsors and other third parties.
		Serono will, however, use personally-identifiable information only in accordance with the version of the Privacy Policy under which the information was collected.
		Rebif is used to treat relapsing forms of MS to decrease the frequency of relapses and delay the occurrence of some of the physical disability that is common in people with MS.
	www.rebif.com /global/rx120.jsp (1063 words)

	Promising Antegren data ruffles Serono
		Serono also highlighted that there was no information on placebo patients, none on what happens following the discontinuation of the product, and no combination data with Avonex.
		Serono indicated that Rebif has long-term safety data stretching back eight years, which is important, given that long-term use of immunosuppressants is linked with increasingly severe side effects.
		Serono has stated that it is not concerned by Antegren and is not planning to run a head-to-head trial with the Biogen product.
	www.bioportfolio.com /news/datamonitor_100.htm (852 words)

	Bold Bets - Serono is muscling its way into the US market with head-to-head trials and big marketing partners. - ... (Site not responding. Last check: 2007-11-02)
		Serono later boldly put its MS drug Rebif (interferon beta1a) up against Biogen's Avonex, a similar interferon, in a head-to-head trial and proved Rebif's superiority.
		Although Serono is a household name in Europe, in the United States it is battling for recognition against the big biotechs based here—Amgen, Genentech, and Biogen-Idec.
		The company was founded in Rome in 1906 by Cesare Serono, a doctor in chemistry and medicine, who extracted lecithin from egg yolks to create a tonic called bioplastina.
	www.pharmexec.com /pharmexec/article/articleDetail.jsp?id=146594 (569 words)

	Serono receives FDA approval for Gonal-f RFF Pen to treat infertility
		Gonal-f® RFF Pen is indicated for induction of ovulation and pregnancy in anovuluatory infertile women in whom the cause of infertility is functional and not due to primary ovarian failure.
		Serono, Inc., located in Rockland, MA, is the US affiliate of Serono, a global biotechnology leader, headquartered in Geneva, Switzerland.
		Serono's research programs are focused on growing these businesses and on establishing new therapeutic areas.
	www.eurekalert.org /pub_releases/2004-05/epr-srf052604.php (816 words)

	Serono - Médico Farmacéutico - Química - Directorio de empresas
		Serono fue una de las primeras compañías en detectar el potencial de la biotecnología en la producción industrial de fármacos, ya a principios de los años ochenta.
		Serono cuenta con instalaciones punteras propias en diversos lugares en Europa (Francia, Suiza e Italia) y en Estados Unidos, que se complementan con alianzas estratégicas y acuerdos con otras compañías biotecnológicas y prestigiosas instituciones.
		En la actualidad, Serono tiene en marcha más de 30 proyectos de investigación distintos, encaminados a desarrollar tanto proteínas como pequeñas moléculas que supongan tratamientos innovadores en las áreas terapéuticas en que estamos presentes, así como en otras.
	www.guiadeprensa.com /quimica/serono.html (1178 words)

	In The Courts \| New York Serono Sales Rep Charged With Bribing Physicians To Prescribe AIDS Wasting Drug Serostim - ...
		Serono management allegedly required the directors to identify the "highest prescribing physicians" in each region and offer "financial incentives" in order to obtain the required number of prescriptions to achieve a sales goal of $6 million in six days, according to a U.S. attorney's office release.
		Part of the plan was to offer an all-expenses-paid trip to the 3rd International Conference on Nutrition and HIV Infection in Cannes, France, in April 1999 in return for writing at least 30 prescriptions for Serostim, according to the court filing.
		Stupak, who left Serono in 2001, is charged with three counts of bribery and could be sentenced to 15 years in prison and required to pay $225,000 in fines,
	www.kaisernetwork.org /daily_reports/rep_index.cfm?DR_ID=27270 (589 words)

	Geneva’s biotech pride, Serono, makes offer for Genset
		Serono, first in Europe and third in the world, and Genset have announced that they have agreed on the terms of a recommended cash tender offer by Serono for all outstanding shares.
		Serono's Offer was unanimously recommended by the board of directors of Genset on June 25.
		Serono will have the competitive advantage of an integrated process combining all the key elements needed to move from understanding the human genome to producing a molecule for human clinical trials.
	www.geneva.ch /sero.htm (597 words)

	Atempo - Trusted Information Lifecycle Management
		Serono was awarded the International James D. Watson 2003 Helix Award from the Biotechnology Industry Organization (BIO) in recognition of the Company's outstanding leadership and highest standards of scientific and product achievement.
		Serono sought to provide data protection for every employee to insure against data loss from both human error and software/hardware failure.
		Serono’s Systems and Storage Architect and project manager Roberto Tolini takes up the story: “We needed a backup solution that would provide full disaster recovery capabilities, point-in-time system restores, and self-service file recovery, all in a single package.
	www.storactive.com /customers/caseStudies/serono.asp (593 words)

	Press release : SERONO CompanynewsGroup
		Such statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of Serono S.A. and affiliates to be materially different from those expected or anticipated in the forward-looking statements.
		Forward-looking statements are based on Serono’s current expectations and assumptions, which may be affected by a number of factors, including those discussed in this press release and more fully described in Serono’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 25, 2004.
		Serono has no responsibility to update the forward-looking statements contained in this press release to reflect events or circumstances occurring after the date of this press release.
	www.companynewsgroup.com /communique.asp?co_id=87257 (1155 words)

	Serono concentra en España su producción mundial de hormona de crecimiento mediante ingeniería genética - Noticias
		La planta de Serono en Tres Cantos es la única planta de biotecnología que existe en nuestro país dedicada a la producción industrial, mediante ingeniería genética, de medicamentos de gran valor terapéutico para las personas.
		Serono ha llevado a cabo un complejo proceso de transferencia tecnológica desde otras plantas del grupo a la de Tres Cantos, para adaptar sus instalaciones a las exigencias de las autoridades sanitarias de Estados Unidos, Europa y Canadá.
		Serono comercializa en más de 80 países bajo el nombre de Saizenâ la hormona de crecimiento recombinante para el tratamiento del déficit de dicha hormona en niños y adultos.
	www.pmfarma.com /noticias/noticias/noti.asp?ref=1874 (516 words)

	CNN.com - Serono profit soars on strong performance for MS drug - Jul. 24, 2001
		Serono plans to pitch its MS drug against Avonex, which enjoys exclusive marketing rights in the U.S. until 2003, this year but needs to convince the U.S. Food and Drug Administration that Rebif is the better of the two drugs.
		Serono's fertility treatment Gonal-F also posted strong growth of 22.5 percent to $114.7 million.
		Shares in Serono rose 2.2 percent to 1,640 Swiss francs in early Zurich trade.
	europe.cnn.com /2001/BUSINESS/07/24/serono/index.html (347 words)

	Novel Oral Treatment for MS Under Development by Serono and Paratek Pharma (Site not responding. Last check: 2007-11-02)
		Serono and Paratek Pharmaceuticals, Inc announced today that they have entered into an agreement to discover, develop and commercialize an orally-available disease modifying treatment for multiple sclerosis (MS).
		Serono will be responsible for the worldwide development and commercialization of compounds arising from the collaboration.
		“Serono's commitment to multiple sclerosis and their extensive research expertise in the fields of neurology, immunology and inflammation were very attractive to Paratek.
	www.medicalnewstoday.com /medicalnews.php?newsid=15571 (1067 words)

	Serono Announces Major Milestone in Identifying the Genes Involved in Multiple Sclerosis
		Serono's mission is to discover and develop innovative products to fight debilitating diseases, such as MS, and improve the quality of life of patients.
		Fully integrated with the global state-of-the-art research facilities of Serono, the Serono Genetics Institute is contributing to create a unique biotech approach that brings human genetics into all stages of the discovery and development process, to increase the quality of Serono's therapeutic molecules.
		Forward-looking statements are based on Serono's current expectations and assumptions, which may be affected by a number of factors, including those discussed in this press release and more fully described in Serono's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 16, 2005.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/03-17-2005/0003202164&EDATE= (851 words)

	Serono results rise on Rebif sales - Boston Business Journal: (Site not responding. Last check: 2007-11-02)
		Serono (NYSE: SRA) said revenue were up 20 percent in the fourth quarter to $679.7 million and 23 percent for the full year to $2.458 billion.
		Serono said Rebif was the fastest-selling MS therapy in the United States last year and remains the dominant market leader internationally.
		Serono is said to be searching in Cambridge or nearby suburbs for space to expand its Massachusetts presence.
	boston.bizjournals.com /boston/stories/2005/01/31/daily38.html?jst=b_ln_hl (715 words)

	INPHARMATICA ANNOUNCES ITS FIRST MILESTONE PAYMENT FROM SERONO - Inpharmatica (Site not responding. Last check: 2007-11-02)
		This first payment to Inpharmatica is for the achievement of a significant milestone in the development of a novel secreted protein, identified by Inpharmatica using PharmaCarta™, the Company’s knowledge-based chemogenomics platform, and delivered to Serono under the terms of a collaboration entered into in July 2001.
		Secreted proteins are an important class of proteins involved in many normal and disease processes and a number are presently on the market as treatments for a variety of diseases or disorders.
		Under the terms of the collaboration, Serono received the right to select an unlimited number of novel protein therapeutics, identified by Inpharmatica using PharmaCarta™, for clinical development and commercialisation.
	www.inpharmatica.co.uk /news/2003/200603.htm (739 words)

	Serono, Pfizer Get Another Chance to Crow About Rebif
		According to Pfizer and Serono, the study found that 75% of patients who received Rebif didn't have a relapse after 24 weeks of treatment, compared with 63% of patients treated with Avonex.
		In March 2002, just after Rebif was approved in the U.S., Biogen asked the FDA to stop Serono from saying that its drug was better than Avonex.
		Serono signed up Pfizer last summer to help market Rebif in the U.S. In early trading, shares of Biogen were down 56 cents to $38.30.
	www.thestreet.com /_tsclsii/tech/marketmovers/10089104.html (359 words)

	This Is MS - Rebif Market Share Growing; Antegren Viewed as Biggest Threat
		Serono plans to grab 30 percent of the $2 billion U.S. market for MS drugs by 2006.
		Shares of Serono have fallen almost 20 percent since Feb. 17, the day before Biogen Idec and Elan said they were planning to ask the U.S. Food and Drug Administration for approval a year earlier than expected.
		Serono, which ranks behind Amgen Inc. and Genentech Inc., has said it's interested in purchasing new therapies to boost its product range outside the areas of multiple sclerosis, fertility, growth and metabolic disease.
	www.thisisms.com /modules.php?name=News&file=print&sid=166 (946 words)

	Forbes.com: UPDATE 3-Serono wins first European psoriasis drug approval (Site not responding. Last check: 2007-11-02)
		Serono shares reversed an early gain as the broader market turned down, falling 1.2 percent to 810 Swiss francs by 1206 GMT, while the DJ Stoxx European healthcare index <.SXDP> eased 0.5 percent.
		Serono is also developing two other drugs -- Onercept and IL-18 bp -- that aim to treat psoriasis, which affects up to two percent of the population and represents a $3 billion market.
		Serono is flush with cash and has said it is on the lookout to license products from other drugmakers.
	www.forbes.com /newswire/2004/03/16/rtr1300066.html (808 words)

	Serono Announces Appointment of New Chief Financial Officer
		Forward- looking statements are based on Serono's current expectations and assumptions, which may be affected by a number of factors, including those discussed in this press release and more fully described in Serono's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 25, 2004.
		Serono has no responsibility to update the forward- looking statements contained in this press release to reflect events or circumstances occurring after the date of this press release.
		SOURCE Serono International S.A. Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/11-10-2004/0002400549&EDATE= (561 words)

	Biotechnology News and Information Portal, biotech jobs and career resources Resources. (Site not responding. Last check: 2007-11-02)
		These\r\nfactors include any failure or delay in Seronos ability to develop new\r\nproducts, any failure to receive anticipated regulatory approvals, any\r\nproblems in commercializing current products as a result of competition or\r\nother factors, our ability to obtain reimbursement coverage for our products,\r\nand government regulations limiting our ability to sell our products.
		The primary goal of this randomized, double-blind, placebo-controlled trial is to assess whether Serostim® induction therapy significantly reduces the marked abnormal accumulation of visceral adipose tissue (intra-abdominal fat) and fat maldistribution which characterize HARS, and whether low-dose maintenance therapy prevents the abnormalities from returning during a continued course of therapy.
		Serono is committed to ensuring rapid completion of the trial and a US registration submission for Serostim as a treatment for this orphan indication."
	www.bioexchange.com /news/news_page.cfm?id=21164 (1024 words)

	Cooley Godward LLP \| News & Publications \| Press Releases \| Serono and Micromet to Collaborate in Development and ...
		Ep-CAM, the target antigen for MT201, is overexpressed with high frequency on most human carcinomas, suggesting that it may have therapeutic potential in the treatment of a broad range of cancers, including prostate, breast, colon, lung, stomach, pancreatic, head & neck, and ovarian cancer.
		With this important addition to our pipeline, Serono's portfolio of novel anti-cancer agents is evolving well." Serono is currently evaluating TACI-Ig in two clinical trials for the treatment of B-cell malignancies.
		In addition to being the world leader in reproductive health, Serono has strong market positions in neurology, metabolism and growth and has recently entered the psoriasis area.
	www.cooley.com /news/pressreleases.aspx?ID=000038769520 (974 words)

	Serono Rep Gets Federal Criminal Charges
		Evan Slavitt, Stupak's attorney, said his client was ordered by Serono — which is headquartered in Geneva and runs its US operations from Massachusetts — to make the offer to doctors in his sales territory.
		Renee Connolly, Serono's US spokesperson, said company policy is not to comment on legal proceedings.
		On March 1, the complaint says, Serono executives announced to Stupak and five other regional sales directors its "$6m-6 Day" plan, in which the representatives would offer a free trip to France in exchange for writing at least 10 Serostim prescriptions.
	www.natap.org /2004/newsUpdates/121604_04.htm (308 words)

Try your search on: Qwika (all wikis)